文献速递眼底病与葡萄膜炎白内障与屈光手术

白内障术后炎症药物治疗预防黄斑囊样水肿的专家观点

Anti-inflammatory Pharmacotherapy for the Prevention of Cystoid Macular Edema After Cataract Surgery.
PubMed 文献 · Am J Ophthalmol · 2021-06-19

本文为专家观点文章,讨论无并发症白内障术后抗炎药物的使用策略与争议,重点在于预防黄斑囊样水肿(CME)导致的不可逆视力丧失。文章讨论了糖皮质激素与非甾体抗炎药(NSAIDs)联合治疗、给药策略及新兴疗法。结论认为术后最佳抗炎药物治疗仍存争议,需要共识定义临床显著CME并开展精心设计的试验。

要点

  • NSAIDs与糖皮质激素联合使用可能加速视力恢复,但长期视力获益证据不足。
  • 新获批的无滴眼液给药系统有前景,相关临床试验正在进行。

核心结论

  • 白内障术后最佳抗炎药物治疗仍存争议,需要共识定义临床显著CME以促进药物比较。
  • 需要精心设计的试验研究局部及缓释给药系统以完善治疗范式。

研究设计与样本

  • 本文为观点文章(Perspective),基于专家评论讨论白内障术后炎症管理。

主要发现

  • 同时处方NSAIDs和糖皮质激素常见,但两类药物机制有重叠。
  • 联合治疗可能加速视力恢复,但NSAIDs改善长期视力结局的证据仍很少。
  • 新获批的无滴眼液给药系统有前景,评估其结局的临床试验正在进行。

临床怎么用

  • 临床可考虑NSAIDs与糖皮质激素联合使用以加速术后视力恢复。
  • 可考虑术前1-3天开始NSAIDs预处理以预防CME。

局限性

  • 本文为专家观点,非系统综述或原始研究,未提供具体数值证据。
  • 术后抗炎药物治疗方案缺乏共识定义和精心设计的试验支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To elucidate strategies for and controversies surrounding the use of anti-inflammatory medications after uneventful cataract surgery, with a focus on the prevention of irreversible vision loss due to cystoid macular edema (CME). DESIGN: Perspective. METHODS: Expert commentary on the management of inflammation after cataract surgery. Discussion includes combination therapy with corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), dosing strategies, and emerging therapies. RESULTS: While prescribing both NSAIDs and corticosteroids for cataract surgery is common, these classes have overlapping mechanisms. Combination therapy may speed visual recovery, but there remains little evidence for improved long-term visual outcomes from NSAIDs. The last 2 decades have seen increasing data on potential benefits of pretreatment with NSAIDs 1-3 days prior to cataract surgery. Simultaneously, newly approved "dropless" delivery systems hold promise, and clinical trials are ongoing to assess outcomes of such formulations. CONCLUSIONS: Optimal pharmacologic treatment for inflammation after cataract surgery remains controversial. A consensus definition for clinically significant CME may facilitate the comparison of anti-inflammatory drugs. And there remains a need for well-designed trials examining both topical and extended-release drug-delivery systems to refine the treatment paradigm.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Taubenslag KJ, Kim SJ, Grzybowski A, et al. Anti-inflammatory Pharmacotherapy for the Prevention of Cystoid Macular Edema After Cataract Surgery. Am J Ophthalmol. 2021. PMID: 34157275. doi:10.1016/j.ajo.2021.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。